Marc de GaridelCEO, Abivax

Marc de Garidel has extensive biopharmaceutical leadership experience with over 40 years in the industry, including as CEO for the last 12 years.  In addition to being the CEO of Abivax, Marc is the Chairman of Ipsen.  He led Abivax through an Initial Public Offering on the Nasdaq in the 4th quarter of 2023, which was the largest ever French biotech IPO on Nasdaq. Under Marc’s leadership, Abivax also secured $150 m in debt financing from two structured debt financing transactions in 2023.